natgillin/translations-raw huggingface dataset:
The Reference Member State was Sweden and the Concerned Member States were Austria, Belgium, Bulgaria, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Netherlands, Norway, Portugal, Romania, Slovenia, Slovak Republic and United Kingdom.
Referenčna država članica je bila Švedska, zadevne države članice pa so bile Avstrija, Belgija, Bolgarija, Češka, Nemčija, Danska, Estonija, Španija, Finska, Francija, Madžarska, Irska, Islandija, Italija, Litva, Luksemburg, Latvija, Nizozemska, Norveška, Portugalska, Romunija, Slovenija, Slovaška republika in Združeno kraljestvo.
The Mutual Recognition Procedure started on 20 September 2007.
Postopek medsebojnega priznavanja se je začel 20. septembra 2007.
The final opinion was converted into a Decision by the European Commission on 11 September 2008.
Končno mnenje je bilo spremenjeno v Odločbo Evropske komisije dne 11. septembra 2008.
These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Te države članice se niso mogle sporazumeti glede medsebojnega priznavanja dovoljenja za promet z zdravilom, ki ga je odobrila referenčna država članica.
The arbitration procedure started on 19 March 2008 with the adoption of a list of questions.
Arbitražni postopek se je začel 19. marca 2008 s sprejetjem seznama vprašanj.
A positive opinion was adopted by majority on 26 June
Odbor je dne 26. junija 2008 z večino glasov sprejel pozitivno mnenje.
Sweden referred the reasons for disagreement to the EMEA on 3 March 2008.
Švedska je agenciji EMEA posredovala razloge za nestrinjanje dne 3. marca 2008.
The Rapporteur was Dr Pierre Demolis (FR) as Rapporteur and Co-Rapporteur(s) was Dr Ingemar Persson (SE).
Poročevalec je bil dr. Pierre Demolis (FR), soporočevalec pa dr. Ingemar Persson (SE).
The Marketing Authorisation Holder provided written explanations on 5 May 2008.
Imetnik dovoljenja za promet z zdravilom je priskrbel pisna pojasnila dne 5. maja 2008.
The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Seznam zadevnih imen zdravil je naveden v Dodatku I. Znanstveni zaključki so na voljo v Dodatku II, povzetek glavnih značilnosti zdravila pa v Dodatku III.
During their June 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Activelle and associated names, that the objections raised by France and Germany should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Med srečanjem junija 2008 je CHMP na podlagi vseh predloženih podatkov in znanstvene razprave v okviru Odbora predstavil svoje mnenje, da je razmerje med koristmi in tveganji za zdravilo Activelle in povezana imena ugodno ter da ugovori, ki sta jih podali Francija in Nemčija, ne smejo preprečiti odobritve dovoljenja za promet z zdravilom, pa tudi da je treba povzetek glavnih značilnosti zdravila, označevanja in navodila za uporabo referenčne države članice spremeniti.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Activelle and associated names International Non-Proprietary Name (INN): Estradiol and norethisterone acetate
ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 29(4)1 ZA ZDRAVILO Activelle in povezana imena Mednarodno nelastniško ime (INN): Estradiol in noretisteron acetat
This refers to endometrial safety of Activelle 0.5 mg/0.1 mg, which had been insufficiently demonstrated according to the CHMP guideline for HRT products (EMEA/CHMP/021/97 rev 1) and this was considered to be of serious public health concern.
To se nanaša na endometrijsko varnost zdravila Activelle, 0,5 mg/0,1 mg, ki v skladu s smernicami CHMP za zdravila za hormonsko nadomestno terapijo (EMEA/CHMP/021/97 rev. 1) ni bila zadostno dokazana, kar predstavlja resen zadržek v zvezi z javnim zdravjem.
Activelle and associated names, estradiol 0.5mg and norethisterone acetate 0.1 mg film-coated tablets is a continuous combined hormone replacement therapy (HRT) for oestrogen deficiency symptoms in women more than one year after menopause.
Zdravilo Activelle in povezana imena, estradiol 0,5 mg in noretisteron acetat, 0,1 mg, filmsko obložene tablete, se uporablja za kontinuirano kombinirano hormonsko nadomestno zdravljenje (HNZ) simptomov pomanjkanja estrogena pri ženskah več kot eno leto po menopavzi.
Novo Nordisk A/S submitted applications for mutual recognition of Activelle and associated names, estradiol 0.5mg and norethisterone acetate 0.1 mg film-coated tablets on the basis of the marketing authorisation granted by Sweden on 3 August 2007.
Družba Novo Nordisk A/S je predložila vloge za medsebojno priznavanje zdravila Activelle in povezana imena, estradiol, 0,5 mg, ter noretisteron acetat, 0,1 mg, filmsko obložene tablete, na podlagi dovoljenja za promet z zdravilom, ki ga je odobrila Švedska dne 3. avgusta 2007.
‘Idiopathic' means that the cause of the disease is unknown.
„Idiopatska“ pomeni, da je vzrok bolezni neznan.
The CHMP also noted the lack of effective alternative treatments.
Prav tako je izpostavil pomanjkanje učinkovitih nadomestnih zdravljenj.
What measures are being taken to ensure the safe and effective use of Esbriet?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Esbriet?
The European Commission granted a marketing authorisation valid throughout the European Union for Esbriet on 28 February 2011.
Evropska komisija je dovoljenje za promet z zdravilom Esbriet, veljavno po vsej Evropski uniji, izdala 28. februarja 2011.
The summary of the opinion of the Committee for Orphan Medicinal Products for Esbriet can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Povzetek mnenja Odbora za zdravila sirote o zdravilu Esbriet je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Other information about Esbriet
Druge informacije o zdravilu Esbriet
In both studies, the main measure of effectiveness was the change in the functioning of the patients' lungs after 72 weeks of treatment, measured by their ‘forced vital capacity' (FVC).
V obeh študijah je bilo glavno merilo učinkovitosti sprememba delovanja bolnikovih pljuč po 72 tednih zdravljenja, ki so jo merili s „forsirano vitalno kapaciteto“ (FVK).
The first study also found Esbriet to be most effective at the higher dose.
V prvi študiji se je tudi pokazalo, da je zdravilo Esbriet najučinkovitejše pri večjem odmerku.
It therefore decided that Esbriet's benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato je zaključil, da so koristi zdravila Esbriet večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Patients who have side effects such as stomach problems, skin reactions to light or significant changes in the levels of liver enzymes may need to take a lower dose at least temporarily.
Pri bolnikih, pri katerih se pojavijo neželeni učinki, kot so težave z želodcem, reakcije kože na svetlobo ali večje spremembe ravni jetrnih encimov, bo morda treba odmerek vsaj začasno zmanjšati.
This is a summary of the European public assessment report (EPAR) for Esbriet.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Esbriet.
The first study also compared two doses of Esbriet (399 mg and 801 mg three times a day).
V prvi študiji so primerjali tudi dva različna odmerka zdravila Esbriet (399 mg in 801 mg trikrat na dan).
Esbriet must not be used by patients already taking fluvoxamine (a medicine used to treat depression and obsessive compulsive disorder) or patients with severe liver or kidney problems.
Zdravila Esbriet ne smejo jemati bolniki, ki že jemljejo fluvoksamin (zdravilo, ki se uporablja za zdravljenje depresije in obsesivno-kompulzivne motnje) ali bolniki s hudimi težavami z jetri ali ledvicami.
For more information about treatment with Esbriet, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Esbriet preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What benefits of Esbriet have been shown in studies?
Kakšne koristi je zdravilo Esbriet izkazalo v študijah?
Esbriet is available as capsules (267 mg) and tablets (267, 534 and 801 mg) that are taken at mealtimes.
Zdravilo Esbriet je na voljo v obliki kapsul (267 mg) in tablet (267 mg, 534 mg in 801 mg), ki se jemljejo ob obroku.
What are the risks associated with Esbriet?
Kakšna tveganja so povezana z zdravilom Esbriet?
The dose of Esbriet is increased steadily, starting with 267 mg three times a day in the first week, 534 mg three times a day in the second week and 801 mg three times a day from the third week onwards.
Odmerek zdravila Esbriet se postopno povečuje, pri čemer se zdravljenje začne z odmerkom v višini 267 mg trikrat na dan v prvem tednu, nadaljuje z odmerkom v višini 534 mg trikrat na dan v drugem tednu, od tretjega tedna naprej pa v višini 801 mg trikrat na dan.
The higher dose results from the first study, combined with the results of the second study (which involved the same higher dose), showed that the average reduction in FVC was 8.5% for patients taking Esbriet compared with 11% for patients taking placebo.
Rezultati pri večjem odmerku v prvi študiji so skupaj z rezultati druge študije (pri kateri so uporabili enak večji odmerek) pokazali, da je bilo povprečno zmanjšanje forsirane vitalne kapacitete pri bolnikih, ki so jemali zdravilo Esbriet, 8,5-odstotno, pri bolnikih, ki so jemali placebo, pa 11-odstotno.
Why is Esbriet approved?
Zakaj je bilo zdravilo Esbriet odobreno?
Because the number of patients with IPF is low, the disease is considered ‘rare', and Esbriet was designated an ‘orphan medicine' (a medicine used in rare diseases) on 16 November 2004.
Ker je bolnikov z idiopatsko pljučno fibrozo malo, velja ta bolezen za redko, zato je bilo zdravilo Esbriet 16. novembra 2004 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Esbriet have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Esbriet upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Esbriet.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The company must also ensure that all doctors who are expected to prescribe Esbriet are provided with information material containing safety information on liver function and light-sensitive reactions.
Prav tako mora zagotoviti, da bodo vsi zdravniki, ki naj bi predpisovali zdravilo Esbriet, prejeli informativno gradivo za zdravnike, ki vsebuje podatke o varnosti v zvezi z delovanjem jeter in reakcijami preobčutljivosti na svetlobo.
The mechanism of action of pirfenidone, the active substance in Esbriet, is not fully understood but it has been shown to reduce the production of fibroblasts and other substances involved in the formation of fibrous tissue during the body's tissue repair process, thereby slowing down the progression of the disease in IPF patients.
Mehanizem delovanja zdravilne učinkovine zdravila Esbriet, pirfenidona, še ni popolnoma znan, vendar je bilo ugotovljeno, da zmanjšuje tvorbo fibroblastov in drugih snovi, ki vplivajo na oblikovanje fibroznega tkiva med procesom obnavljanja tkiv, ter tako upočasnjuje napredovanje bolezni pri bolnikih z idiopatsko pljučno fibrozo.
IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath.
Idiopatska pljučna fibroza je dolgotrajna bolezen, pri kateri se v pljučih nenehno tvori fibrozno brazgotinasto tkivo, ki povzroča stalen kašelj, pogoste okužbe pljuč in zelo oteženo dihanje.
What is Esbriet and what is it used for?
Kaj je zdravilo Esbriet in za kaj se uporablja?
The most common side effects with Esbriet during clinical studies were nausea (feeling sick), rash, tiredness, diarrhoea, dyspepsia (heartburn), loss of appetite, headache and photosensitivity reactions (sunburn-like reactions following exposure to light).
V kliničnih študijah zdravila Esbriet so glede neželenih učinkov najpogosteje poročali o navzeji (slabosti), izpuščajih, utrujenosti, driski, dispepsiji (zgagi), izgubi teka, glavobolu in reakciji preobčutljivosti na svetlobo (kožnih reakcijah, podobnih sončnim opeklinam, zaradi izpostavljenosti svetlobi).
Esbriet can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the diagnosis and treatment of IPF.
Predpisovanje in izdaja zdravila Esbriet je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem idiopatske pljučne fibroze.
Esbriet contains the active substance pirfenidone.
Zdravilo Esbriet vsebuje zdravilno učinkovino pirfenidon.
Esbriet was more effective than placebo (a dummy treatment) at slowing down the worsening of lung function in two main studies involving a total of 779 IPF patients.
Zdravilo Esbriet je bilo pri upočasnjevanju poslabšanja delovanja pljuč učinkovitejše od placeba (zdravila brez zdravilne učinkovine) v dveh glavnih študijah, v katerih je sodelovalo skupno 779 bolnikov z idiopatsko pljučno fibrozo.
FVC is the maximum amount of air the patient can breathe out forcefully after taking in a deep breath, which decreases as the condition gets worse.
Forsirana vitalna kapaciteta je največja količina zraka, ki jo lahko bolnik naglo izdihne po globokem vdihu, kar pa se pri poslabšanju bolezni zmanjšuje.
The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that Esbriet has been shown to slow down the progression of IPF, as measured by FVC, without serious risks for patients.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je menil, da zdravilo Esbriet upočasni napredovanje idiopatske pljučne fibroze, kakor je bilo izmerjeno s forsirano vitalno kapaciteto, brez resnega tveganja za bolnike.
For the full list of all side effects reported with Esbriet, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Esbriet, glejte navodilo za uporabo.
In the first study, the patients taking Esbriet had a smaller reduction in FVC after 72 weeks than the patients taking placebo.
V prvi študiji je bilo po 72 tednih pri bolnikih, ki so jemali zdravilo Esbriet, zmanjšanje forsirane vitalne kapacitete manjše kot pri bolnikih, ki so jemali placebo.
The company that makes Esbriet has set up a post-authorisation safety study in order to collect additional information on patients prescribed Esbriet and suspected side effects.
Družba, ki proizvaja zdravilo Esbriet, je pripravila varnostno študijo po izdaji dovoljenja za promet z njim, s katero zbira dodatne podatke o bolnikih, ki se zdravijo s tem zdravilom, in možnih neželenih učinkih.
Esbriet is a medicine used to treat adults with mild to moderate idiopathic pulmonary fibrosis (IPF).
Zdravilo Esbriet se uporablja za zdravljenje odraslih z blago do zmerno obliko idiopatske pljučne fibroze.
How is Esbriet used?
Kako se zdravilo Esbriet uporablja?
How does Esbriet work?
Kako zdravilo Esbriet deluje?
administration
Karenca
Package size Withdrawal period
Velikost pakiranja
This overview was last updated in 10-2018.
Pregled je bil nazadnje posodobljen 10-2018.
Further information on Trelegy Ellipta can be found on the Agency's website: ema.europa.eu/ medicines/Human/EPAR/Trelegy-Ellipta.
Nadaljnje informacije o zdravilu Trelegy Ellipta so na voljo na spletni strani agencije: ema.europa.eu/ medicines/Human/EPAR/Trelegy-Ellipta.
Trelegy Ellipta received a marketing authorisation valid throughout the EU on 15 November 2017.
Za zdravilo Trelegy Ellipta je bilo 15. novembra 2017 izdano dovoljenje za promet, veljavno po vsej EU.
The European Medicines Agency therefore decided that Trelegy Ellipta's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Trelegy Ellipta večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
After 24 weeks, patients taking Trelegy Ellipta had their FEV1 (the maximum volume of air they could breathe out in one second) improve by 142 ml.
Po 24 tednih se je pri bolnikih, ki so jemali zdravilo Trelegy Ellipta, vrednost FEV1 (največja količina zraka, ki jo lahko oseba izdihne v eni sekundi) izboljšala za 142 ml.
More serious side effects include pneumonia (which may affect up to 1 in 10 people).
Resnejši neželeni učinki vključujejo pljučnico (ki se lahko pojavi pri največ 1 bolniku od 10).
What measures are being taken to ensure the safe and effective use of Trelegy Ellipta?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Trelegy Ellipta?
Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis.
Zdravilo Trelegy Ellipta se uporablja za vzdrževalno (redno) vsakodnevno zdravljenje.
This compares with an average reduction of 29 ml seen in patients taking the combination of budesonide and formoterol over the same period.
Ta vrednost se je povprečno zmanjšala za 29 ml pri bolnikih, ki so v enakem obdobju jemali kombinacijo budezonida in formoterola.
Trelegy Ellipta (fluticasone furoate / umeclidinium bromide / vilanterol)
Trelegy Ellipta (flutikazonfuroat/umeklidinijev bromid/vilanterol)
In this study, Trelegy Ellipta reduced the rate of moderate and severe exacerbations over one year by 15% compared with treatment with vilanterol and fluticasone furoate, and by 25% compared with treatment with vilanterol and umeclidinium bromide.
V tej študiji je zdravilo Trelegy Ellipta zmanjšalo stopnjo zmernih in resnih poslabšanj bolezni v enem letu za 15 % v primerjavi z zdravljenjem z vilanterolom in flutikazonfuroatom in za 25 % v primerjavi z zdravljenjem z vilanterolom in umeklidinijevim bromidom.
It works by attaching to beta-2 receptors in some types of muscle cells.
Deluje tako, da se veže na receptorje beta-2 v nekaterih vrstah mišičnih celic.
The most common side effects with Trelegy Ellipta (which may affect up to 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat), headache and upper respiratory tract infection (nose and throat infection).
Najpogostejši neželeni učinki zdravila Trelegy Ellipta (ki se lahko pojavijo pri največ 1 bolniku od 10) so nazofaringitis (vnetje nosu in žrela), glavobol in okužba zgornjih dihal (okužba nosu in grla).
Patients treated with Trelegy Ellipta also reported improved health compared with those treated with the comparator treatment.
Bolniki, ki so jemali zdravilo Trelegy Ellipta, so poročali tudi o izboljšanju zdravja v primerjavi z bolniki, ki so bili zdravljeni s primerjalnim zdravilom.
It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.
Vsebuje učinkovine flutikazonfuroat, umeklidinijev bromid in vilanterol.
As for all medicines, data on the use of Trelegy Ellipta are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Trelegy Ellipta stalno spremljajo.
Side effects reported with Trelegy Ellipta are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Trelegy Ellipta, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trelegy Ellipta have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Trelegy Ellipta upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Long-acting beta-2 agonists widen the airways; corticosteroids reduce inflammation in the airways and lungs; and muscarinic receptor antagonists cause the muscles of the airways to relax.
Dolgodelujoči agonisti adrenergičnih receptorjev beta-2 razširjajo dihalne poti; kortikosteroidi zmanjšujejo vnetje v dihalnih poteh in pljučih; antagonisti muskarinskih receptorjev pa povzročajo, da se mišice dihal sprostijo.
Other information about Trelegy Ellipta
Druge informacije o zdravilu Trelegy Ellipta
Trelegy Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD).
Trelegy Ellipta je zdravilo, ki se uporablja za lajšanje simptomov zmerne do hude kronične obstruktivne pljučne bolezni (KOPB).
An overview of Trelegy Ellipta and why it is authorised in the EU
Pregled zdravila Trelegy Ellipta in zakaj je odobreno v EU
Umeclidinium bromide is a muscarinic receptor antagonist.
Umeklidinijev bromid je antagonist muskarinskih receptorjev.
Vilanterol is a long-acting beta-2 agonist.
Vilanterol je dolgodelujoči agonist adrenergičnih receptorjev beta-2.
This reduces the release of substances involved in the inflammation process, such as histamine, thereby reducing inflammation and helping to keep the airways clear and allowing the patient to breathe more easily.
S tem se zmanjša sproščanje snovi, ki sodelujejo v procesu vnetja, na primer histamina, zato se zmanjša vnetje, kar pripomore k ohranjanju prehodnosti dihalnih poti in bolniku olajša dihanje.
Regarding the safety profile of the medicine, the most frequent side effects reported with Trelegy Ellipta were similar to those with the individual active substances of the medicine and are well known.
Glede varnostnega profila zdravila Trelegy Ellipta so bili najpogostejši neželeni učinki, o katerih so poročali pri uporabi tega zdravila, podobni kot pri posameznih učinkovinah zdravila in so dobro znani.
Why is Trelegy Ellipta authorised in the EU?
Zakaj je bilo zdravilo Trelegy Ellipta odobreno v EU?
It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors (targets) in various types of immune cells.
Deluje podobno kot kortikosteroidni hormoni, ki naravno nastajajo v telesu, pri čemer se veže na receptorje (prijemališča) v različnih vrstah imunskih celic in tako zmanjša dejavnost imunskega sistema.
Trelegy Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a longacting muscarinic antagonist.
Zdravilo Trelegy Ellipta se uporablja pri odraslih, pri katerih bolezen ni dovolj dobro nadzorovana s kombinacijo inhalacijskih zdravil, ki jo sestavljata dolgodelujoči agonist adrenergičnih receptorjev beta-2 in kortikosteroid ali dolgodelujoči muskarinski antagonist.
What is Trelegy Ellipta and what is it used for?
Kaj je zdravilo Trelegy Ellipta in za kaj se uporablja?
Trelegy Ellipta contains three active substances, which work in different ways to widen the airways and improve breathing in COPD.
Zdravilo Trelegy Ellipta vsebuje tri učinkovine, ki različno delujejo na širjenje dihalnih poti in izboljšanje dihanja pri KOPB.
What benefits of Trelegy Ellipta have been shown in studies?
Kakšne koristi je zdravilo Trelegy Ellipta izkazalo v študijah?